Take Homes in Multiple Myeloma

Take Homes in Multiple Myeloma

Source: Healio Interview
Disclosures: Richardson reports consulting for and/or receiving research support from AstraZeneca, Celgene/BMS, GSK, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio and Takeda.
June 23, 2022
1 min watch
Save

VIDEO: Secondary cancers found after stem cell transplants for multiple myeloma

Source: Healio Interview
Disclosures: Richardson reports consulting for and/or receiving research support from AstraZeneca, Celgene/BMS, GSK, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio and Takeda.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.

While Richardson notes that much of the side effect results were expected, the study produced some findings of concern, namely the secondary cancer signal and a transient drop of quality of life in transplant patients.

“While fortunately the numbers were low, we did see significantly more cases of [acute myeloid leukemia] and [myelodysplastic syndromes] with early transplant,” Richardson said.

Reference:

  • Richardson,P, et al. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.